Home/Pipeline/NI101B3

NI101B3

Alzheimer's Disease

PreclinicalActive

Key Facts

Indication

Alzheimer's Disease

Phase

Preclinical

Status

Active

Company

Neurimmune

About Neurimmune

Neurimmune is a Swiss, privately-held biotech founded in 2006, specializing in discovering and developing first-in-class antibody therapeutics for protein aggregation diseases. Its core Reverse Translational Medicine™ platform analyzes immune cells from elderly donors to generate fully human antibodies with high selectivity and low immunogenicity risk. The company has built a diversified clinical-stage pipeline targeting ATTR-CM, ALS, and Alzheimer's, advancing programs through strategic partnerships with major pharma while retaining early-stage innovation autonomy.

View full company profile

Therapeutic Areas

Alzheimer's Disease Amyotrophic Lateral Sclerosis ATTR Cardiomyopathy Spinal Cord Injury Systemic Amyloidosis

Other Alzheimer's Disease Drugs

Drug	Company	Phase	Status
NUZ-001	Neurizon Therapeutics	Preclinical	Active
ALZN002	Alzamend Neuro	Preclinical	Research
P021	Phanes Biotech	Preclinical	Active
PB43D	Phanes Biotech	Preclinical	Active
UB-311	Vaxxinity	Phase 2	Active
Lecanemab	BioArctic	Launched	Active (Commercial)
BAN2401	BioArctic	Preclinical	Active
Undisclosed Programs	johnson-and-johnson-innovative-medicine	Pipeline	Active
MK-6240 (florquinitau)	Lantheus Medical Imaging	Regulatory Filing	Filed
NAV-4694 (flutafuranol)	Lantheus Medical Imaging	Phase 3	Active
LNTH-2620/PI-2620	Lantheus Medical Imaging	Phase 3	Recruiting
itMSCs	Stemedica Cell Technologies	Clinical Development	Active